MX2022016118A - Formulaciones orales y usos de las mismas. - Google Patents

Formulaciones orales y usos de las mismas.

Info

Publication number
MX2022016118A
MX2022016118A MX2022016118A MX2022016118A MX2022016118A MX 2022016118 A MX2022016118 A MX 2022016118A MX 2022016118 A MX2022016118 A MX 2022016118A MX 2022016118 A MX2022016118 A MX 2022016118A MX 2022016118 A MX2022016118 A MX 2022016118A
Authority
MX
Mexico
Prior art keywords
oral formulations
salts
compounds
methods
pharmaceutical compositions
Prior art date
Application number
MX2022016118A
Other languages
English (en)
Spanish (es)
Inventor
Xing Dai
Yueheng Jiang
Yaolin Wang
Yanqin Liu
Xiaomei Wang
Original Assignee
Inventisbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventisbio Co Ltd filed Critical Inventisbio Co Ltd
Publication of MX2022016118A publication Critical patent/MX2022016118A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022016118A 2020-06-19 2021-06-18 Formulaciones orales y usos de las mismas. MX2022016118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/097036 WO2021253380A1 (en) 2020-06-19 2020-06-19 Oral formulations and uses thereof
PCT/CN2021/100806 WO2021254471A1 (en) 2020-06-19 2021-06-18 Oral formulations and uses thereof

Publications (1)

Publication Number Publication Date
MX2022016118A true MX2022016118A (es) 2023-02-09

Family

ID=79268491

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016118A MX2022016118A (es) 2020-06-19 2021-06-18 Formulaciones orales y usos de las mismas.

Country Status (9)

Country Link
US (1) US20230263782A1 (cg-RX-API-DMAC10.html)
EP (1) EP4168011B1 (cg-RX-API-DMAC10.html)
JP (1) JP7802018B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230026415A (cg-RX-API-DMAC10.html)
CN (1) CN115996723A (cg-RX-API-DMAC10.html)
AU (1) AU2021291257A1 (cg-RX-API-DMAC10.html)
CA (1) CA3179791A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022016118A (cg-RX-API-DMAC10.html)
WO (2) WO2021253380A1 (cg-RX-API-DMAC10.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004175795A (ja) 2002-11-13 2004-06-24 Takeda Chem Ind Ltd 薬物の放出性に優れた医薬組成物
TW200803850A (en) 2006-03-06 2008-01-16 Wyeth Corp Tablet formulations and processes
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
AP2015008858A0 (en) * 2013-05-28 2015-11-30 Astrazeneca Ab Chemical compounds
CN109362222B (zh) 2016-02-05 2021-03-19 益方生物科技(上海)股份有限公司 选择性雌激素受体降解物及其用途
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
MA46563B1 (fr) 2016-10-24 2024-01-31 Janssen Sciences Ireland Unlimited Co Compositions dispersibles
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
CN108864080B (zh) * 2017-05-09 2021-10-15 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的四环类化合物及其应用
JP7448541B2 (ja) 2018-12-24 2024-03-12 インベンティスバイオ カンパニー リミテッド 選択的エストロゲン受容体分解剤の新規な塩

Also Published As

Publication number Publication date
JP2023532209A (ja) 2023-07-27
EP4168011A4 (en) 2024-08-07
WO2021254471A1 (en) 2021-12-23
WO2021253380A1 (en) 2021-12-23
EP4168011A1 (en) 2023-04-26
EP4168011B1 (en) 2025-11-12
CN115996723A (zh) 2023-04-21
CA3179791A1 (en) 2021-12-23
KR20230026415A (ko) 2023-02-24
US20230263782A1 (en) 2023-08-24
EP4168011C0 (en) 2025-11-12
AU2021291257A1 (en) 2023-01-19
JP7802018B2 (ja) 2026-01-19

Similar Documents

Publication Publication Date Title
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
JOP20220351A1 (ar) صيغ من 19-nor c3، وسترويد 3- بيرازول-c21-n- بيرازول ليس به استبدال وطرق استخدامه
PH12020550341A1 (en) Niraparib formulations
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
JOP20220332A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
MX2021011811A (es) Protacs que degradan el receptor de estrogeno.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2018007844A (es) Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
GEAP202516634A (en) Heteroaryl compounds for the treatment of pain
PH12019501724A1 (en) Estrogen receptor modulators
WO2018176079A8 (en) Berberine alkaloids in the prevention and/or treatment of intestinal disease
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
TW200800946A (en) Substituted piperazines as metabotropic glutamate receptor antagonists
MX2021007687A (es) Sales novedosas de degradadores selectivos de receptores de estrogeno.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2025012705A (es) Complejos cristalinos entre velagliflozina y agentes formadores de cocristales seleccionados, metodos para su preparacion y su uso en la preparacion de medicamentos
WO2022204344A3 (en) Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2025008370A (es) Formas cristalinas de 6-(3-((5-cloro-2-metoxipiridin)-3-sulfonamido)-2,6-difluorofenil)-n-metilimidazo[1,5-a]pirazin-1-carboxamida y metodos para usar las mismas